Wegovy Tablets for Men in the UK: What You Need to Know

# Wegovy Tablets for Men in the UK: What You Need to Know

Oral Wegovy is approved for all eligible adults regardless of sex, and the clinical evidence from the OASIS trials includes male participants. But men considering oral semaglutide often have specific questions that standard patient information does not address: do results differ for men? What happens to muscle mass? How does alcohol factor in? And does it matter that most of the weight loss content online seems aimed squarely at women?

This guide answers those questions with the available evidence, and gives practical guidance relevant to men starting or considering oral Wegovy in the UK.

> Wegovy tablets are a prescription-only medicine. Always consult a qualified healthcare professional before starting or changing treatment. Eligibility requires a clinical assessment — you cannot self-prescribe.

—

## Do Wegovy tablets work differently for men?

The short answer is: broadly the same mechanism, with some biologically relevant differences in how results manifest.

The underlying pharmacology is identical. Semaglutide acts on GLP-1 receptors in the GI tract and brain in men exactly as it does in women. Appetite suppression, gastric emptying slowdown, and the neurological reduction in food reward are not sex-specific. The MHRA-approved indication and dosing schedule are the same for both sexes.

Where differences emerge is in body composition, fat distribution, and metabolic baseline. Men typically carry a higher proportion of visceral fat (fat around the abdominal organs) relative to subcutaneous fat. Visceral fat is metabolically active and responds more readily to GLP-1 treatment and calorie deficit. This often means men see faster early visible results in abdominal circumference — the waist measurement tends to drop before the scale does, particularly in the first two to three months. This can be motivating, even when scale weight is moving more slowly.

Men also tend to have higher absolute muscle mass and a higher basal metabolic rate than women of comparable body weight. This affects the calorie arithmetic: at equivalent doses and appetite suppression, men may sustain a slightly larger calorie deficit, which can support faster weight loss in the early months. That said, the OASIS trial results across the full population reflect a distribution that includes both sexes, and meaningful individual variance exists within each sex.

GI side effects may be marginally less prevalent in men than in women at equivalent doses, based on observations from trials of other GLP-1 agents. The evidence on this is not robust enough to be stated as a reliable difference — it is an observation from clinical practice rather than a primary trial outcome. Many men experience the same GI adjustment phase as women, particularly in weeks one to four at the starting dose.

—

## Who are the men starting oral Wegovy?

The men seeking out oral Wegovy in the UK tend to fall into several broad groups, and understanding which group you are in shapes what you can realistically expect.

One significant cohort is men who previously avoided or declined injectable Wegovy specifically because of needle phobia. Needle aversion is considerably more prevalent in men than is commonly acknowledged — and the weekly self-injection required by injectable Wegovy was a genuine barrier for this group. The oral tablet removes that barrier entirely, making treatment accessible to men who would not have proceeded with the injection.

Another group is men with BMI in the 27–35 range who have weight-related conditions — hypertension, high triglycerides, pre-diabetes, obstructive sleep apnoea — and want a pharmaceutical option to support what diet and exercise have not achieved alone. This is precisely the licensed population for oral Wegovy, and men in this category are often highly motivated and engaged patients.

A third group is men with higher BMIs (35+) who have been on a waiting list for, or have been declined for, bariatric services, and who see oral Wegovy as an accessible alternative path.

—

## The testosterone question

Obesity is associated with reduced testosterone in men. The relationship is bi-directional: low testosterone promotes fat accumulation (particularly visceral fat), and higher levels of body fat reduce testosterone production through aromatisation — conversion of testosterone to oestrogen in adipose tissue. This hormonal dynamic means that many men with obesity have measurably lower testosterone than they would have at a healthy body weight.

Oral Wegovy does not contain testosterone and has no direct hormonal effect. However, significant weight loss — of the order of 10–15% of body weight as seen in the OASIS trials — can improve testosterone levels indirectly, by reducing the adipose tissue volume that drives aromatisation. Men who lose significant weight often report improved energy, libido, and mood — effects that are consistent with modest testosterone improvement as well as the general metabolic benefits of weight loss.

This is not a guarantee, and oral Wegovy is not a testosterone replacement. If you have symptoms of low testosterone — fatigue, low mood, reduced libido, reduced muscle strength — these should be assessed and managed through your GP or an appropriate specialist, separately from weight management treatment.

—

## Muscle mass: why it matters more for men

Weight loss of any kind — whether through diet, exercise, medication, or surgery — involves loss of both fat and lean mass. The proportion that is lean mass versus fat mass depends substantially on exercise, particularly resistance training.

For men, preserving muscle during a calorie deficit is more important than it is often framed. Muscle mass determines resting metabolic rate; losing significant lean mass during weight loss means that when treatment eventually stops, the metabolic rate is lower and weight regain is faster. Maintaining muscle also has direct quality-of-life benefits for strength, physical capability, and long-term health.

The practical implication: men starting oral Wegovy should include resistance training in their exercise routine, not as an optional extra but as a deliberate strategy to protect lean mass during treatment. This does not require a gym membership — bodyweight exercises at home are sufficient if done consistently. Protein intake should be adequate: at least 1.6g per kg of target body weight per day is a standard evidence-based target during weight loss for muscle preservation.

Cardio exercise is valuable for cardiovascular health and calorie burn, but resistance training is the specific tool for lean mass protection. If you only have time for one, and muscle preservation is the priority, resistance training is the higher-value choice during GLP-1 treatment.

—

## Practical notes for men on the morning fasting routine

The 30-minute pre-eating fast required for oral Wegovy is occasionally cited by men as a scheduling challenge, particularly those who go to the gym early or have demanding early-morning work schedules. The protocol does not preclude morning exercise — it simply requires that the tablet is taken before exercise, with the fast observed before and after the tablet.

One approach that works well: take the tablet immediately on waking, do 30–40 minutes of light activity (stretching, walking, a gentle warm-up, email and planning tasks, a shower and preparation), then eat breakfast. This integrates naturally with most morning routines without requiring significant restructuring.

Pre-workout supplementation is a common concern. Most stimulant-based pre-workout drinks or protein shakes should not be consumed during the 30-minute window — they constitute “drinking something other than water.” Check with your prescriber about timing if you use pre-workout supplements regularly.

—

## Alcohol and oral Wegovy

Men in the UK consume alcohol at higher average rates than women, and this is directly relevant to treatment outcomes. Alcohol adds calories, disrupts sleep, impairs the hormonal environment that weight loss depends on, and weakens the GI lining in ways that amplify semaglutide side effects. Heavy alcohol use significantly undermines the results achievable with oral Wegovy.

On a practical note, many men on semaglutide report that their alcohol tolerance drops noticeably during treatment. Less food in the stomach (due to appetite suppression), slower gastric emptying, and the drug’s effects on gastric motility mean that alcohol enters the bloodstream more rapidly than before. People on GLP-1 drugs who drink the same amount they did before starting treatment can find they feel intoxicated faster and feel worse the next day. This is a genuine physiological change, not a placebo effect.

The advice is not to stop drinking if you are not alcohol-dependent, but to be aware of this changed response and to moderate intake, both for the treatment’s sake and for safety.

—

## The stigma question

A disproportionate number of weight loss medication conversations in the UK media and online are framed around women’s experiences. This does not reflect the clinical reality — men are just as eligible, just as likely to benefit, and just as deserving of effective treatment for obesity. A generation of fitness culture that frames weight loss as a matter of discipline and effort has made it harder for some men to seek pharmaceutical support for a hormonal and metabolic condition.

Oral semaglutide works by correcting a biological imbalance — the appetite and satiety signalling disruption that drives obesity in metabolically susceptible people. Using it is no more “cheating” than taking medication for any other hormonally driven condition.

—

## Frequently asked questions

### Are the weight loss results from Wegovy tablets the same for men and women?

The overall efficacy is broadly similar — the OASIS trials found approximately 16.6% average weight loss at 64 weeks across the population, which includes both men and women. Men may see earlier changes in abdominal circumference (visceral fat loss), while women may see different patterns of fat distribution change. Individual variation within each sex is greater than average differences between sexes.

### Does oral Wegovy affect testosterone levels in men?

Not directly. The drug has no hormonal action on testosterone production. However, significant weight loss achieved through any means — including GLP-1 treatment — can modestly improve testosterone levels by reducing aromatisation in adipose tissue. This is a secondary benefit of weight loss rather than a direct effect of semaglutide.

### Will I lose muscle on Wegovy tablets?

Some lean mass loss occurs with any weight loss, but it can be significantly reduced by maintaining adequate protein intake (at least 1.6g per kg of target body weight per day) and by including regular resistance training in your routine. Without these measures, a higher proportion of weight lost may be lean mass rather than fat. With them, most weight loss is from fat stores.

### Can I drink alcohol while taking Wegovy tablets?

Alcohol is not contraindicated, but it significantly undermines results and increases the likelihood of GI discomfort. Many men on oral semaglutide find their alcohol tolerance reduces noticeably due to faster gastric absorption with less food in the stomach. Moderate intake is advisable, and heavy or binge drinking is likely to compromise your results and increase side effect burden.

### What if my GP says Wegovy isn’t for men?

This would be incorrect clinical information. Oral Wegovy is MHRA-licensed for adults with the relevant BMI criteria regardless of sex. If your GP is unfamiliar with the oral tablet formulation, referring them to the MHRA licence and the OASIS trial publications would be appropriate. Private prescribers who specialise in weight management are generally more familiar with the full landscape of GLP-1 treatment options.

—

*This article is for informational purposes only and does not constitute medical advice. Wegovy tablets (oral semaglutide) are a prescription-only medicine available in the UK. Always consult a registered UK healthcare professional before starting any weight management treatment. CompareWegovyPrices.co.uk is not affiliated with Novo Nordisk.*